Therapeutic efficacy of a new cephamycin, MT-141, in compromised mice.
The antibacterial activity of MT-141 against Escherichia coli and Proteus morganii in compromised mice was investigated and compared with that of latamoxef, cefmetazole and cefoxitin. The bactericidal activity of MT-141 in short-term contact with E. coli and P. morganii was markedly enhanced when combined with mouse serum, and the activity of MT-141 was greater than the activities of the three reference drugs. The antibacterial activities of MT-141 in the liver, spleen and kidney of neutropenic and Sarcoma 180 tumor-bearing mice infected with E. coli and P. morganii were superior to the activities of the reference drugs. MT-141 was more potent than cefmetazole and cefoxitin, and similar to latamoxef in potency against systemic P. morganii infection in Sarcoma 180 tumor-bearing mice.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001770:Blood Bactericidal Activity; D002513:Cephamycins / Q000494:pharmacology / Q000627:therapeutic use*; D003167:Complement Activation / Q000187:drug effects; D006168:Guinea Pigs; D007108:Immune Tolerance; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009374:Neoplasms, Experimental / Q000382:microbiology; D009503:Neutropenia / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002513:Cephamycins; C046079:cefminox